Biopharmaceutical benchmarks 2010

Biopharmaceutical benchmarks 2010

Over the past four years, several new types of experimental biologic treatment have received commercial registration, but the emergence of biosimilars represents the biggest shift in the biologic approval landscape.

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Nature biotechnology 2010-09, Vol.28 (9), p.917-924
1. Verfasser: Walsh, Gary
Format: Artikel
Sprache:eng
Schlagworte:
631/61/51
692/308/153
Agriculture
Antibodies, Bispecific - economics
Antibodies, Bispecific - therapeutic use
Benchmarking - standards
Benchmarks
Bioinformatics
Biological Products - economics
Biological treatment
Biomedical and Life Sciences
Biomedical Engineering/Biotechnology
Biomedicine
Biopharmaceutics - economics
Biopharmaceutics - standards
Biotechnology
Cancer Vaccines - economics
Drug Approval - statistics & numerical data
Drug Industry - economics
Drug Industry - standards
Drugs, Generic - economics
Europe
Experiments
FDA approval
feature
Life Sciences
Marketing - economics
Medical research
Pharmaceutical industry
Protein Engineering - economics
United States
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Over the past four years, several new types of experimental biologic treatment have received commercial registration, but the emergence of biosimilars represents the biggest shift in the biologic approval landscape.
ISSN:1087-0156
1546-1696
DOI:10.1038/nbt0910-917